GPRC5D is an orphan receptor expressed on myeloma cells and hard keratinised tissue (skin, nails, tongue), explaining its toxicity profile. Talquetamab (bispecific) is approved; GPRC5D CAR-T (arlocabtagene autoleucel) is in phase 3.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · GPRC5D is a second myeloma target used when BCMA-directed drugs stop working.
- 1 · What it is
GPRC5D is a second myeloma target used when BCMA-directed drugs stop working.
- 2 · What goes wrong in cancer
GPRC5D is an orphan class C GPCR.
- 3 · How drugs use it
1 product aims at GPRC5D: bispecific antibodies. Because it sits on the outside of the cell, it can be reached from the bloodstream: antibodies flag the cell, ADCs deliver a toxin, radioligands deliver radiation, and CAR-T or bispecifics bring a T cell.
Biology
GPRC5D is an orphan class C GPCR.
- Multiple myeloma
How common it is, by cancer
| Cancer | Prevalence | Measure | Note | Source |
|---|---|---|---|---|
| Multiple myeloma | 60-80% | High expression by IHC/RNA | Expression correlates with high risk | Wikipedia |
Approximate, population-level figures; the measure column says what was counted. Ranges show the midpoint as a bar.
Latest papers
topQuery for this target: (TITLE:"GPRC5D" OR ABSTRACT:"GPRC5D") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about GPRC5D, not a curated reading list.
Pages like this
not linked directly; found by shared links- TargetCD3
Shares Talquetamab, MagnetisMM-3: elranatamab, a second BCMA bispecific, with a switch to fortnightly dosing after response, T-cell engagers (bispecific), Multiple myeloma and the tag t-cell-engager-target.
- TargetDLL3
Shares T-cell engagers (bispecific) and the tag t-cell-engager-target.
- TargetBCMA
Shares BCMA-directed therapy → GPRC5D-directed therapy, Multiple Myeloma Research Foundation (MMRF), Plan the second CAR-T target before the first one is lost, Comprehensive Cancer Center Mainfranken, University Hospital Würzburg and the tag t-cell-engager-target.
- TrialMonumenTAL-1
Shares BCMA-directed therapy → GPRC5D-directed therapy, Talquetamab, Multiple myeloma.
- Key paperMajesTEC-1: teclistamab, an off-the-shelf BCMA bispecific antibody, in heavily pretreated myeloma
Shares BCMA-directed therapy → GPRC5D-directed therapy, Talquetamab, MagnetisMM-3: elranatamab, a second BCMA bispecific, with a switch to fortnightly dosing after response, T-cell engagers (bispecific).
- TermHigh-risk cytogenetics (myeloma)
Shares Multiple Myeloma Research Foundation (MMRF), Multiple myeloma.
- ProductTeclistamab
Shares BCMA-directed therapy → GPRC5D-directed therapy, Comprehensive Cancer Center Mainfranken, University Hospital Würzburg, MagnetisMM-3: elranatamab, a second BCMA bispecific, with a switch to fortnightly dosing after response, T-cell engagers (bispecific).
- TermR-ISS / R2-ISS staging
Shares Multiple Myeloma Research Foundation (MMRF), Multiple myeloma.